As more gene and CAR-T therapies enter the market, especially in therapeutic categories with more patients such as cancer, experts say manufacturers will have to up their game in establishing the true value of their therapies, and work closely with payers on payment agreements. Precision for Value experts Jeremy Schafer and Alex Grosvenor offer their perspectives in this MedAd News cover story.
To read the full article, please click here.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
